特利加压素与托拉塞米治疗失代偿期肝硬化并发肝肾综合征患者疗效比较

doi:10.3969/j.issn.1672-5069.2015.01.021

Abstract

Wu Jun. Comparison of terlipressin and torsemide in the treatment of patients with decompensated cirrhosis and hepatorenal syndrome[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 78-79.

[1] 杨辛泉,杨玲. 肝肾综合征的诊治.临床消化病杂志,2010,22（3）:187-189.
[2] 王静艳,窦晓光. 肝肾综合征发生的危险因素及防治. 中国实用内科杂志,2013,33（9）:687-689.
[3] Fasolato S,Angeli P,Dallagnese L,et al. Renal failure and bacterial infections in patients with cirrhosis:epidemiology and clinical features. Hepatology,2007,45（1）:223-229.
[4] 尚佳,曹青. 肝肾综合征的诊断. 中华肝脏病杂志,2011,19（3）:165-166.
[5] Boyer TD,Sanyal AJ,Garcia-Tsao G,et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl,2011,17（11）:1328-1332.
[6] 张伦理. 肝肾综合征的发病机制. 中华肝脏病杂志,2011,19（3）:163-164.
[7] 李秋生,蒋宇波. 持续性注射托拉塞米治疗肝硬化顽固性腹水的疗效观察. 中国医药指南,2012,10（24）:76-77.
[8] 胡瑞钺,田波,喻建勇.托拉塞米的临床应用与比较探讨. 中国医药导报,2010,7（2）:189-190.
[9] 刘瑞婵,王效然. 托拉塞米与其他泮利尿剂的临床应用比较. 山西医药杂志,2013,42（3）:287-289.
[10] Triantos CK,Samonakis D,Thalheimer U,et al. Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol,2010,22（4）:481-486.
[11] 于淙,王鲁文,龚作炯. 特利加压素治疗肝肾综合征有效性及安全性的Meta分析. 实用肝脏病杂志,2013,16（2）:119-121.
[12] 赵春明,周建红,陆敏学,等. 国产特利加压素治疗肝硬化肝肾综合征的疗效研究. 临床合理用药,2014,7（2）:27-29.
[13] 刘海霞,李娟,姚勤伟,等. 特利加压素治疗肝硬化失代偿期并发肝肾综合征疗效观察.传染病信息,2010,23 （2）:90-92.
[14] 唐东,吴建新,朱长红,等. 特利加压素联合白蛋白治疗Ⅰ型肝肾综合征的疗效和安全性的评价.胃肠病学和肝病学杂志,2010,19（10）:875-879.
[15] 俞哲,叶坚虹,王琛,等. 特利加压素治疗肝肾综合征的疗效分析. 中国临床药理学与治疗学,2009,14（10）:1164-1167.
[16] 肖扬,卢成鸿,周岳进,等.特利加压素与去甲肾上腺素在肝肾综合征治疗中的比较. 肝脏,2012,17（3）:159-161.
[17] 闫勇,柏涛. 特利加压素联合白蛋白治疗肝肾综合征35例. 中西医结合肝病杂志,2012,22（6）:377-378.

Comparison of terlipressin and torsemide in the treatment of patients with decompensated cirrhosis and hepatorenal syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[6]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[7]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[8]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[9]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[12]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[13]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.